Research & Development
ReForm Biologics and KBI Biopharma Partner to Improve Biopharmaceutical Formulations
10 April 2018 - - US-based biotherapeutics company ReForm Biologics and biopharmaceutical contract services company KBI Biopharma, Inc. have formed a strategic partnership to make improved biopharmaceutical formulations, the companies said.
Through this collaboration, KBI and ReForm will help customers extend product lifecycles, enable improved dosing for patients, and enhance manufacturing efficiencies.
As part of the collaboration, KBI will provide services to ReForm to further develop and validate its biologic formulation platform while also gaining access to ReForm's proprietary technology.
Reform will maintain the ability to utilize its formulation technologies directly with its pharmaceutical and biotechnology partners.
As part of the strategic partnership, KBI has made an equity investment in ReForm Biologics. Financial terms of the agreement were not disclosed.
KBI provides fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. To date, the company has served more than 250 clients around the world. KBI operates facilities in Durham and Research Triangle Park, Boulder and Louisville, The Woodlands, and San Diego.
ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Its patented FDA-friendly technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for its biopharmaceutical partners.
With multiple industry alliances to date, the company offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.


Related Headlines